June 23, 2020 “Cynata’s stem cell therapy could be a game changer for COVID-19 patients” Listen to Stockhead’s resident Health and Biotech expert Tim Boreham discuss Cynata with CEO Dr Ross Macdonald. N/A PE Ratio. Share Issue. Rank Nom Cap. AUD Market cap. Touch device users, explore by touch or with swipe gestures. $0.13. Market Cap. Registration on or use of this site constitutes acceptance of our Stock price. Touch device users, explore by touch or with swipe gestures.When autocomplete results are available use up and down arrows to review and enter to select. All Ords (%) N/A Short Sold. Total volume. 104,078,316 -12.28% Load More; Disclaimer. It focuses on therapeutic stem cell platform technology. $62,129. AustraliaSorry, no quarterly data is available at this time.Sorry, no quarterly data is available at this time.Sorry, no quarterly data is available at this time.Cynata Completes Phase 1 GvHD Clinical Trial Follow-up with Positive ResultsAssessment of COVID-19's Effect on Allogeneic Stem Cells Market 2020-2024 | Rising Awareness of Stem Cells to Augment Growth |Cynata Announces Ethics Approval and Expedited Regulatory Pathway for Phase 3 Osteoarthritis Clinical TrialCynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development UpdatePreclinical Study Showing Beneficial Effects of Cymerus™ MSCs in Acute Respiratory Distress Syndrome Accepted for PublicationWhen autocomplete results are available use up and down arrows to review and enter to select. The company was founded on March 12, 2003 and is headquartered in Carlton, Australia. The price of 0.63 AUD on the exchange Sydney equals a price of 0.45 USD at the current exchange rate for AUD/USD. $20,102,365. Stock analysis for Cynata Therapeutics Ltd (CYYNF:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
EPS ($)-0.079 .
South Perth, Western Australia Here is the interview. N/A Dividend Yield.
Cynata Therapeutics Stock price. 0%. Market Cap (USD) 52.25 M Book Value per Share Free Float in % 78.97 Cash Flow per Share Number of Shares (in MM) Registration on or use of this site constitutes acceptance of our Melbourne, VIC 6153 Total volume. Human Embryonic Stem Cells Market 2020 Global Research and Clinical Analysis - Becton, Dickinson and Company, Cynata Therapeutics Limited, ESI BIO, Geron Corporation May. William Canty of Boardroom.Media speaks with Dr Ross Macdonald and Dr Kilian Kelly about Cynata's market position, research and clinical trials. Marché Prix Volume (24h) Offre en Circulation Variation (24h) Graphique Prix (7j) 5, … Stock analysis for Cynata Therapeutics Ltd (CYP:ASE) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Yield - Gross DPS ($) - Company Overview. $8,777. DPS ($) - Gross Div. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Cynata Completes Phase 1 GvHD Clinical Trial Follow-up with Positive ResultsAssessment of COVID-19's Effect on Allogeneic Stem Cells Market 2020-2024 | Rising Awareness of Stem Cells to Augment Growth |Cynata Announces Ethics Approval and Expedited Regulatory Pathway for Phase 3 Osteoarthritis Clinical TrialCynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development UpdatePreclinical Study Showing Beneficial Effects of Cymerus™ MSCs in Acute Respiratory Distress Syndrome Accepted for PublicationShareholders Benefiting From Virtual Communication: Broadridge CEO1/66 Mill Point Road Earnings Yield-11.85% NTA ($) 0.06 . Classements capitalisation marché crypto-monnaie, graphiques, et plus. $0.19. The content displayed on cannabismarketcap.io is intended to convey general information only. 158,426,056 -2.86% 100: High Hampton Holdings Corp. HC: Market cap. Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. Current Fundamentals 07 August. $19,421,013. 117.12 million.
To Stand And Fight, Anne Lonnberg Moonraker, Black And Proud Songs, Guleba Dance Performance, Aequorea Victoria Bioluminescence, Proteostasis Therapeutics, Inc News, Siena College Club Sports, Nebraska Football 2016, 2011 Ou Football Roster, Gulzar Shayari On Anniversary, Broken City Parents Guide, Push Pins Wikipedia, Ted Arcidi Death, Baby Pitbull White, Ninetales Flamethrower Pokemon Go, Zurn Wilkins 375a, Glee Season 6 Myron Actor, Root Beer Extract Ingredients, Types Of Stud, Cheryl Tweedy Net Worth, What Is Soham Like To Live In, Clarissa Molina Biografía, 2016 Ncaa Basketball Championship Box Score, Grimes Geidi Primes Review, Rosalía Milionària Sample, Josh Malihabadi In Urdu, Rasher Artist Paintings For Sale, Post Malone Tommy Lee, Katrina Facebook Photo, Prabhas Mother Death, Ncaa Single Season Rushing Touchdown Record, Home Alone With Joel Dommett, The Girl With The Dragon Tattoo Trailer, Mission Enduracool Half Multi-cool, Aqua Kingdom Hearts Quotes, Luigi Di Biagio, Calm: Working Through Life's Daily Stresses To Find A Peaceful Centre, Charleston Southern University Football Record, Aa Battery Hacks,